Back to today’s briefing

Story perspectives

UK Study Reveals Genetic Insights for Breast Cancer Treatment

10/11/2025

33 7

Summary

Story summary

The UK study finds that 27% of breast cancer cases have genetic features guiding personalized treatment, potentially benefiting over 15,000 women annually.
It identifies mutations such as homologous recombination deficiency (HRD) and patterns indicating treatment resistance in breast cancer.
The AMPLITUDE trial finds that adding niraparib to standard prostate cancer therapy reduces disease progression by nearly 50% in men with BRCA mutations.

1 of 1

Story summary

The UK study finds that 27% of breast cancer cases have genetic features guiding personalized treatment, potentially benefiting over 15,000 women annually.
It identifies mutations such as homologous recombination deficiency (HRD) and patterns indicating treatment resistance in breast cancer.
The AMPLITUDE trial finds that adding niraparib to standard prostate cancer therapy reduces disease progression by nearly 50% in men with BRCA mutations.